Cargando…

Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients

For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target trough blood level is 3–8 μg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to maintain blood levels of 5–8 ug/L (designated RD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fuchs, Uwe, Zittermann, Armin, Schulz, Uwe, Gummert, Jan F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345239/ https://www.ncbi.nlm.nih.gov/pubmed/22577516 http://dx.doi.org/10.1155/2012/976921

Ejemplares similares

Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
por: Liu, Jinyu, et al.
Publicado: (2017)

Donor–recipient risk assessment tools in heart transplant recipients: the Bad Oeynhausen experience
por: Schramm, Rene, et al.
Publicado: (2021)

Impact of maintenance immunosuppressive therapy on the fecal microbiome of renal transplant recipients: Comparison between an everolimus- and a standard tacrolimus-based regimen
por: Zaza, Gianluigi, et al.
Publicado: (2017)

Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response
por: Costard-Jäckle, Angelika, et al.
Publicado: (2022)

Efficacy and Safety of Low-Dose Cyclosporine with Everolimus and Steroids in de novo Heart Transplant Patients: A Multicentre, Randomized Trial
por: Zuckermann, Andreas, et al.
Publicado: (2011)

The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial
por: Van Keer, Jan, et al.
Publicado: (2017)

Renal Function in Patients with or without a Left Ventricular Assist Device Implant During Listing for a Heart Transplant
por: Zittermann, Armin, et al.
Publicado: (2020)

Everolimus in Heart Transplantation: An Update
por: Hirt, Stephan W., et al.
Publicado: (2013)

BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression
por: Barraclough, Katherine A., et al.
Publicado: (2011)

Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients
por: Brunkhorst, Lena Caroline, et al.
Publicado: (2015)

An open-label randomized clinical trial to evaluate the efficacy of everolimus versus tacrolimus in triple maintenance immunosuppressive therapy for kidney transplant patients
por: Assis, B.P.S., et al.
Publicado: (2021)

Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression
por: Zuckermann, Andreas, et al.
Publicado: (2015)

Treatment of De Novo Renal Transplant Recipients With Calcineurin Inhibitor–free, Belatacept Plus Everolimus–based Immunosuppression
por: Peddi, V. Ram, et al.
Publicado: (2023)

(584) Safety of Immunosuppression Maintenance in Heart Transplant Recipients with Covid-19: A Single Center Experience
por: Amione Guerra, J., et al.
Publicado: (2023)

Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy
por: Larsson, Pierre, et al.
Publicado: (2023)

Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients
por: Zwart, Tom C., et al.
Publicado: (2020)

Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial
por: Nashan, Bjorn, et al.
Publicado: (2015)

Sirolimus and everolimus clearance in maintenance kidney and liver transplant recipients: Diagnostic efficiency of the concentration/dose ratio for the prediction of trough steady-state concentrations
por: Bouzas, Lorena, et al.
Publicado: (2010)

Everolimus Based Immunosuppression Strategies in Adult Lung Transplant Recipients: Calcineurin Inhibitor Minimization Versus Calcineurin Inhibitor Elimination
por: Ivulich, Steven, et al.
Publicado: (2023)

Everolimus induced pneumonitis in a lung transplant recipient
por: Arunachalam, Ambalavanan, et al.
Publicado: (2018)

The Benefit of Sirolimus Maintenance Immunosuppression and Rabbit Antithymocyte Globulin Induction in Liver Transplant Recipients That Develop Acute Kidney Injury in the Early Postoperative Period
por: Duhart, Benjamin T., et al.
Publicado: (2015)

Nonclassical Vitamin D Action
por: Zittermann, Armin, et al.
Publicado: (2010)

A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients
por: Chadban, Steven J, et al.
Publicado: (2014)

A 3 year post‐intervention follow‐up on mortality in advanced heart failure (EVITA vitamin D supplementation trial)
por: Zittermann, Armin, et al.
Publicado: (2020)

A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT
por: Goralczyk, Armin D, et al.
Publicado: (2010)

Exploring the safety and efficacy of adding ketoconazole to tacrolimus in pediatric renal transplant immunosuppression
por: Méndez, Sindy, et al.
Publicado: (2020)

Graft loss among renal-transplant recipients with early reduction of immunosuppression for BK viremia
por: Azar, Marwan M, et al.
Publicado: (2017)

Independent Association of Circulating Vitamin D Metabolites with Anemia Risk in Patients Scheduled for Cardiac Surgery
por: Ernst, Jana B., et al.
Publicado: (2015)

Switching from allopurinol to febuxostat: efficacy and safety in the treatment of hyperuricemia in renal transplant recipients
por: Li, Yanchun, et al.
Publicado: (2019)

Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation
por: Kelsh, Shelby E., et al.
Publicado: (2018)

Maintenance of the EBV-specific CD8(+) TCRαβ repertoire in immunosuppressed lung transplant recipients
por: Nguyen, Thi HO, et al.
Publicado: (2017)

Introduction of everolimus in kidney transplant recipients at a late posttransplant stage
por: Uchida, Junji, et al.
Publicado: (2018)

Combined low-dose everolimus and low-dose tacrolimus after Alemtuzumab induction therapy: a randomized prospective trial in lung transplantation
por: Benazzo, Alberto, et al.
Publicado: (2021)

Efficacy and Safety of Everolimus With Reduced Tacrolimus in Liver Transplant Recipients: 24-month Results From the Pooled Analysis of 2 Randomized Controlled Trials
por: Lee, Sung-Gyu, et al.
Publicado: (2020)

Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection
por: Xue, Yan, et al.
Publicado: (2017)

Belatacept for Maintenance Immunosuppression in Lung Transplantation
por: Hui, Christine, et al.
Publicado: (2014)

Development and validation of a LASSO-based prediction model for immunosuppressive medication nonadherence in kidney transplant recipients
por: Dong, Lei, et al.
Publicado: (2023)

Enhanced Humoral Immune Response After COVID-19 Vaccination in Elderly Kidney Transplant Recipients on Everolimus Versus Mycophenolate Mofetil–containing Immunosuppressive Regimens
por: de Boer, Silke E., et al.
Publicado: (2022)

Everolimus and papillomavirus lesions in female renal transplant recipient: A case report
por: Simundic, T., et al.
Publicado: (2018)

1383. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant Recipients
por: Sun, Hsin-Yun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jqqtj81n0l45q4aq0j0q750nl6